Skye Bioscience, Inc.

Contributing Author

Recent Articles by Skye Bioscience, Inc.

Jul-30	Skye Bioscience to Announce Second Quarter 2025 Financial Results and Business Update on August 7, 2025 SKYE GlobeNewswire
Jun-23	Skye Bioscience Shares Nimacimab "Anatomy of Progress" Video Series and Highlights Preclinical CB1 Antibody Data Presented at the American Diabetes Association's 85th Scientific Sessions SKYE GlobeNewswire
Jun-17	Skye Bioscience to Present Expanded Preclinical CB1 Antibody Data at the American Diabetes Association's 85th Scientific Sessions SKYE GlobeNewswire
May-22	Skye Bioscience to Participate in Upcoming Investment Conferences SKYE GlobeNewswire
May-19	Skye Bioscience Establishes Partnership with Arecor Therapeutics to Develop Enhanced Formulation of Obesity Candidate Nimacimab SKYE GlobeNewswire
May-13	Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) SKYE GlobeNewswire
May-13	Skye Bioscience Clinical Model Demonstrating Necessity of Peripheral CB1 Inhibition for Weight Loss Presented at European Congress on Obesity SKYE GlobeNewswire
May-08	Skye Bioscience Reports First Quarter 2025 Results and Highlights Nimacimab Differentiation in Obesity SKYE GlobeNewswire
May-07	Skye Bioscience to Announce 2025 First Quarter Financial Results on May 8th, 2025 SKYE GlobeNewswire